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ABSTRACT
Background: Patient self-monitoring (PSM) of oral
anticoagulation therapy (OAT) can improve anticoagulant
control, but poor uptake and high dropout rates have
prompted suggestions that PSM is suitable for only a
minority of patients in the UK.
Aims: To determine whether PSM could be a viable
alternative to regular hospital anticoagulant clinic atten-
dance, if offered from the start of treatment.
Methods: 318 consecutive patients referred, for the first
time, to an anticoagulation clinic were assessed for
eligibility using established criteria. Patients electing for
PSM attended training and, following successful assess-
ment, performed a capillary blood INR every two weeks or
more frequently if directed to do so by the anticoagulation
clinic. Primary outcome measures were uptake of PSM
and the percentage time in target therapeutic INR range
(TIR) compared to patients electing for routine clinic care.
Results: Of 318 patients referred for OAT, 188 were
eligible for PSM. 84 (26%) elected to self-monitor, of
whom 72 (23%) remained self-monitoring or had
completed their course of treatment at the end of the
audit. Self-monitoring patients had significantly better
anticoagulant control than those receiving routine hospital
anticoagulation clinic care (TIR 71% vs 60%, p=0.003)
and significantly less time outside critical limits, ie, INR
,1.5 or .5.0 (0.45% vs 2.04%, p=0.008).
Conclusions: Patients offered PSM from the start of
treatment show increased uptake compared to previous
UK studies and a level of oral anticoagulation control
comparable to that reported in previous clinical trials.
An estimated 950 000 people in the UK receive oral
anticoagulant therapy (OAT) and the numbers are
increasing at approximately 10% per year. The
main driver for this expansion is the increasing use
of OAT for stroke prevention in patients with
atrial fibrillation, where less than 25% of patients
are thought to be receiving OAT.
1
Several studies in the UK have shown the quality
of care achieved by patient self-monitoring of oral
anticoagulation to be at least as good as that
attained by hospital or primary care anticoagula-
tion clinics.
2–7 However, these studies used only
selected patients who were already established on
warfarin and managed in anticoagulation clinics
for several months prior to enrolment.
Furthermore, the uptake of self-monitoring was
highly variable (10–41%) and the dropout rate in
most studies has been high (9–42%),
8 prompting
suggestions that self-monitoring of OAT is suitable
for only a minority of patients. A recent review of
studies performed in the UK suggested that only
14% of all eligible patients would conduct long-
term self-monitoring of UK OAT.
1 In the majority
of studies, the total population from which
patients were selected was not stated, making it
difficult to assess uptake in absolute terms. In our
previous studies,
24where, as was the case in other
UK studies, self-monitoring was offered to patients
established on oral anticoagulation, we found that
many patients were discouraged by the clinical trial
setting, rather than self-monitoring per se. Others
were reassured by the familiarity of the hospital
anticoagulation clinic, and were reluctant to
change to self-monitoring for this reason. We also
identified non-compliance as a cause of poor
anticoagulation control and increased dropout
rates.
In the UK, patients should expect to be within
their own target therapeutic range for at least 60%
of the time
9 and, therefore, this is also the standard
that any alternative model of OAT management
should achieve. It has been suggested that an
improvement of 10% in time in therapeutic range
over routine care is required if a method is to be
considered superior.
3 Previous studies conducted in
the UK have demonstrated percentage time in
therapeutic range (%TIR) of 61–71% for patients
who were self-testing only, and 70–76% for
patients who were self-testing and self-dosing (ie,
patient self-management).
1
The aim of this audit was to determine whether
self-monitoring of oral anticoagulation from the
start of treatment and outside trial conditions, is
acceptable to patients and a viable alternative to
regular attendance at the anticoagulant clinic.
PATIENTS AND METHODS
The study was a prospective closed cohort audit of
318 consecutive patients referred for oral antic-
oagulation between July 2005 and March 2007.
These patients, who had not previously received
oral anticoagulation, were assessed for suitability
for self-monitoring, using established criteria,
10 ie,
patients with known drug or alcohol abuse,
atypical INR target ranges, anticipated short
therapy duration physical or intellectual impair-
ment, which would preclude self-monitoring, and
patients with language barriers unless a named
carer or interpreter was available. No other
assumptions were made about the patients’ ability
to self-monitor. The Joint UCL/UCLH
Committees on the Ethics of Human Research
deemed this an audit of clinical practice and, as
such, ethical approval was not required.
Protocol
Patients who expressed a desire to self-monitor
attended a nurse-led training course, comprising
two sessions, which covered effects of diet,
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care (POC) monitor (CoaguChek S, Roche Diagnostics, Basel,
Switzerland). Following a successful assessment, patients were
then asked to perform a capillary blood INR once every two
weeks. They contacted the anticoagulation clinical nurse
specialists (CNS) with their INR result by phone and were
advised by the CNS of dose changes and their next test date.
Dosing was performed by the CNS using computer assisted
dosing (4S DAWN Clinical Software, Milnthorpe, UK). CNS
were permitted to override the computerised decision support
software. The manufacturer’s internal quality control was
performed as per UK guidelines
10 and external quality control
was achieved by six-monthly parallel testing,
11 in which the
patient’s POC device was compared to a reference POC device.
Evidence of non-compliance was investigated and retraining
given if required. Those patients who did not want to self-
monitor, or who had still not made a decision after 2 months,
remained under the care of the routine hospital anticoagulation
clinic. All patients were asked to report any problems with
bruising, bleeding or thrombosis. A major bleed was defined as
that requiring hospitalisation and/or blood transfusion.
After a suitable period of familiarisation (at least 6 weeks),
self-monitoring patients were asked if they would like to
self-manage their OAT. Those expressing an interest were given
additional training in dose-adjustment using an algorithm
supplied by the clinic. After a successful assessment, these
patients commenced self-management (ie, self-testing and self-
dosing of OAT). All patients undertaking self-monitoring sign a
contract with the Trust which includes agreement to undertake
self-monitoring as specified by the anticoagulation clinic, when
to contact the clinic, when to undertake quality control (QC)
checks (with QC preparations supplied by the Trust), and for
review and external quality assessment.
Analysis
Percentage TIR was calculated using the method of linear
interpolation, described by Rosendaal et al.
12 Data from the first
6 weeks of treatment were not included in the %TIR analysis,
as OAT control is known to be poor during this period.
13
Patients with unusually narrow therapeutic target ranges were
excluded from all analyses. All patients with less than five INR
results (after the initial six-week period) were also excluded
from the %TIR analysis. The proportions of INR tests within,
below and above the therapeutic range were also recorded. As
the risks of thrombosis and bleeding are known to increase
exponentially at INRs ,1.5 and .5.0 respectively,
14 the
Figure 1 Study protocol.
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calculated. The data showed non-normal distribution, so two-
tailed non-parametric methods were used; the Wilcoxon signed
rank test was used to test for differences between median values
for paired data, and the Mann–Whitney U test was used for
independent groups. A p value of ,0.05 was considered
statistically significant.
RESULTS
In total, 188/318 consecutive patients referred for oral anti-
coagulation for the first time, were eligible for self-monitoring.
Eleven patients were excluded from all further analysis because
they had non-standard target INR ranges. Another 119 patients
were judged to be ineligible for self-monitoring according to
criteria set out in the British Committee for Standards in
Haematology
10 guidelines. Of the 188 eligible patients, 84 (44%)
agreed to self-monitor while 104 declined or failed to make a
decision within two months of their first appointment (fig 1).
Of the remaining 68/84 (81%) patients, 26 completed their
course of treatment and 42 were still self-monitoring at the end
of the 20-month audit period. Four patients had fewer than five
self-monitoring results because the duration of treatment was
shorter than anticipated; these data were therefore excluded
from the time in therapeutic range analysis. Of the 104/188
patients electing for routine anticoagulation clinic care, only 88
had five or more data points after the initial six-week period and
only these 88 were included in the statistical analysis. Self-
monitoring patients were significantly younger than those
electing for routine care (58 vs 68 years of age, p,0.001) and the
increased proportion of patients with atrial fibrillation receiving
routine care reflected this. Men and women were distributed
equally between the treatment groups (table 1).
Therapeutic INR control
The median %TIR was significantly higher in the self-
monitoring patients than in those receiving routine antic-
oagulation clinic care (71% vs 60%, p=0.003). In those patients
who had been self-monitoring (n=28) or receiving routine care
(n=27) for at least one year, the %TIR showed a further
improvement compared with the %TIR in patients receiving
routine anticoagulation clinic care (%TIR 74% (95% CI 69.9 to
80.6) vs 64% (95% CI 60.8 to 69.7), p=0.01) (table 2). In the
patients who elected to self-manage, the median %TIR was 74%
(95% CI 65.6 to 82.2).
The median time between tests was 11 days (range 4–22) in
the self-testing patients and 18 days (range 5–45) in the patients
receiving routine care. When the percentage times outside
critical limits (INR ,1.5 or .5.0) were studied, patients who
monitored their own INR showed a significant reduction in the
amount of time that they were outside these limits when
compared to those patients receiving routine anticoagulation
clinic care (median 0.45% vs 2.04%, p=0.008) (table 3).
Adverse events
We had 59.3 patient-years of follow-up data for the self-
monitoring patients, during which there was one major bleed,
five minor bleeds and two cases of thrombosis. One patient died
prior to training due to an unrelated medical condition. The
incidence of major bleeds was 1.7 per 100 patient-years, minor
bleeds 8.4 per 100 patient-years and thrombosis 3.4 per 100
patient-years. We had 73.9 patient years of follow-up for the
patients receiving routine care, during which there were four
major bleeds (requiring blood transfusion or hospitalisation),
eleven minor bleeds and one case of thrombosis. The incidence
of major bleeds was 5.4 per 100 patient-years, minor bleeds 16.2
per 100 patient-years and thrombosis 1.4 per 100 patient-years.
DISCUSSION
We have audited the acceptability and efficacy of self-monitor-
ing of OAT, when offered at the start of initial anticoagulant
treatment. Other than to exclude patients for whom self-
monitoring was inappropriate, recruitment was non-selective;
26% of all patients (44% of eligible patients) agreed to self-
monitor. Most published studies used the number of eligible
patients as the denominator, making it difficult to accurately
assess total uptake, but we believe that our uptake of 26%
represents an improvement on previous UK studies.
1 As with
previous studies, a significant number of patients dropped out
during or shortly after training (14%), but most of the patients
who started self-monitoring completed their course of treat-
ment or continued to self-monitor after the end of the audit
period (94%). A recent systemic review
1 reported that only 14%
of eligible patients in the UK would conduct long-term
monitoring of OAT, whereas 36% of eligible patients
referred to our anticoagulation clinic were able and willing to
self-monitor when offered self-monitoring at the start of
Table 1 Patient demographics
Number or median
Self-test Routine care
Male (n) 43 54
Female (n) 41 51
Median age (years) (95% CI) 58* (53.6 to 63.0) 68 (63.0 to72.0)
Indications for anticoagulation
Atrial fibrillation 32 59
Replacement heart valve 8 3
Venous thromboemboli 36 40
Cardiovascular prophylaxis 7 1
Other 1 2
Target INR range
1.5–2.5 1 2
2.0–3.0 72 100
2.5–3.5 4 1
3.0–4.0 7 2
*p,0.001.
Table 2 Percentage time in target therapeutic range
Self-test
(n=67)
Routine care
(n=88) p Value
Median % time in therapeutic range 71 (64.1 to 75.3) 60 (55.0 to 63.2) 0.003
% of tests below therapeutic range 22 30 ,0.0001
% of tests in therapeutic range 58 49
% of tests above therapeutic range 20 21
Table 3 Percentage time outside critical control limits (INR ,1.5 or
.5.0)
Self-monitor
(n=67)
Routine care
(n=88) p Value
Median % time outside critical
control range
0.45 (0.0 to 1.8) 2.04 (0.68 to 4.34) 0.008
% of tests below critical limit 3.4 9.0 ,0.0001
% of tests within critical limits 93.3 88.8
% of tests above critical limit 3.3 2.2
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patients were younger than the clinic population as a whole,
1
but we found no gender-related difference in uptake.
The %TIR for self-monitoring patients in this audit is similar
to that observed in previous studies in the UK
2–7 and a recent
study performed in the Netherlands,
15 and superior to that in a
large Spanish study.
16 Most other studies of self-monitoring of
OAT were performed in countries where specialised hospital
anticoagulant clinics are not normal clinical practice.
Consequently, it is not appropriate to discuss these studies here.
While the uptake and retention of patients in our audit were
superior to those in previous studies performed in the UK and
the Netherlands (where anticoagulation is usually undertaken
in specialist hospital-based clinics), recruitment was higher in
the Spanish study
16 and is typically much higher (60–70%) in
Germany, where self-monitoring is widely practiced.
17 The
reasons for this are not entirely clear, but reimbursement and
patient motivation have been cited as possible reasons.
3
This audit had several limitations. As this was an audit of a
new service provision, no randomisation was performed. The
patients who elected for routine anticoagulation clinic care were
older than the self-monitoring patients and they may have been
predisposed to poorer OAT control. The difference in testing
intervals between the two groups makes comparison of %TIR
problematic and the shorter interval between testing may have
been contributory to the higher %TIR in the self-monitoring
patients.
Self-monitoring of OAT has been shown to reduce the
incidence of thrombotic and haemorrhagic complications
18 and
it may enhance the quality of life in some patients including
those who travel frequently, who are in employment or
education, and who find it difficult to travel to clinics.
1
Although this study was not powered to assess the rate of
adverse events, our data showed a trend towards reduced
bleeding and thrombotic events in self-monitoring patients.
While it is unlikely that self-monitoring of OAT will become
cost effective compared to specialist anticoagulant clinics in the
UK,
1 the National Institute for health and Clinical Excellence
recommends that patients with atrial fibrillation who require
long-term anticoagulation should be considered for self-mon-
itoring if preferred by the patient and eligibility criteria are
met.
19 Test-strips for self-monitoring are now available on the
Drug Tariff, but several barriers to self-monitoring remain.
Quality control (QC) preparations are not available on
prescription and some patients are reluctant to perform QC,
highlighting the importance of addressing the supply of QC
preparations and a contract with the Trust specifying when QC
testing should be undertaken. Many GPs refuse to prescribe
test-strips and some Primary Care Trusts refuse to fund self-
monitoring. The General Medical Services Contract National
Enhanced Service is open to interpretation on issues surround-
ing funding of self-monitoring, which may limit progress on its
implementation. Some patients see the price of the monitors as
a major obstacle to self-monitoring.
We conclude that self-monitoring is acceptable to many
patients if offered at the start of treatment and it is also
efficacious. Our data suggest that a quarter of unselected
patients referred for oral anticoagulation choose self-monitor-
ing; they achieve a quality of oral anticoagulation comparable to
that reported in previous UK clinical trials.
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Take-home messages
c Self-monitoring offered at the start of oral anticoagulation is
associated with improved uptake and fewer dropouts.
c Outside trial conditions, self-monitoring patients achieve a
quality of anticoagulant control, which may be superior to that
attained in routine specialist anticoagulation clinics.
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